Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
NCT00673439 · University of Louisville · PHASE2 · terminated · last registry update 2019-11-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “study terminated due to low accrual” | – | Registry record, University of Louisville |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SERPINC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-09-11Phase 3 first posted: Australian National University, Nebulised unfractionated heparin (UFH) (NCT04545541)
- 2020-09-02Phase 3 first posted: University Medical Center Groningen, Heparin + LMWH (NCT04536272)
- 2020-07-23Phase 3 first posted: University of Melbourne, (Arm Closed) Nafamostat Mesilate + (Arm Closed) Enoxaparin (NCT04483960)
- 2020-06-01Phase 3 first posted: Rutgers, The State University of New Jersey, Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (NCT04410328)
- 2020-05-05Phase 3 first posted: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Heparin + Placebos (NCT04374799)
- 2020-04-24Phase 3 first posted: Unity Health Toronto, Therapeutic Anticoagulation (NCT04362085)
- 2020-02-18Phase 3 first posted: Damian Ratano, Subcutaneous Heparin (NCT04273607)
- 2019-09-12Phase 3 first posted: Copenhagen University Hospital, Rigshospitalet, Alteplase 20 Mg Powder for Solution for Injection Vial (NCT04088292)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04067505)
- 2019-08-26Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Rivaroxaban + Warfarin (NCT04066764)
- 2019-06-11Phase 3 first posted: Mt. Sinai Medical Center, Miami, Edetate Disodium (NCT03982693)
- 2019-06-04Phase 3 first posted: Genzyme, a Sanofi Company, Fitusiran (NCT03974113)
- 2018-11-27Phase 3 first posted: Genzyme, a Sanofi Company, Fitusiran (NCT03754790)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision